As we have previously reported, thousands of lawsuits have been filed against Takeda Pharmaceutical Company for its medication Actos after studies revealed that diabetics taking the drug may be at an increased risk of developing bladder cancer. In 2011, the U.S. Food and Drug Administration (FDA) warned that use of the diabetes
Actos
Federal Judge Appoints Plaintiffs’ Leadership Team in Actos Litigation
By Martin P. Schrama on
Posted in Actos, Defective Drugs
The Honorable Rebecca F. Doherty, who is overseeing the federal Actos cases centralized in Louisiana, has appointed 19 plaintiffs’ attorneys to manage the litigation. As we have previously reported, recent studies allegedly show that diabetics taking Actos may be at an increased risk of developing bladder cancer. A recent Bloomberg article stated that Takeda Pharmaceutical…
Multi-District Litigation Granted in Actos Bladder Cancer Litigation
By Martin P. Schrama on
Posted in Actos, Defective Drugs
The United States Judicial Panel on Multi-District Litigation (MDL) met on December 1, 2011, in Savannah, Georgia, to hear arguments regarding whether all federal Actos cases should be consolidated into multi-district litigation (MDL) and, if so, where the cases should be consolidated.
As we have previously reported, recent studies allegedly show that diabetics taking Actos…
Still Waiting on MDL Decision in Actos Litigation
By Kevin M. Hart on
Posted in Actos, Defective Drugs
The United States Judicial Panel on Multi-District Litigation (JPML) met on Thursday, December 1, 2011, in Savannah, Georgia, to hear arguments regarding whether all federal Actos cases should be consolidated into multi-district (MDL). Recent studies allegedly show that diabetics taking Actos may be at an increased risk of developing bladder cancer. The JPML has yet…
Panel Scheduled to Meet to Consider MDL Treatment in Actos Litigation
By Craig S. Hilliard on
Posted in Actos, Defective Drugs
The United States Judicial Panel on Multi-District Litigation (MDL) is scheduled to meet on December 1, 2011, in Savannah, Georgia to hear arguments on whether all federal Actos cases should be centralized, pursuant to 28 U.S.C.§ 1407, for coordinated or consolidated pretrial proceedings, and if so, which federal district is the appropriate forum for these…
Actos Class Action Filed in Louisiana
By Stefanie Colella-Walsh on
Posted in Actos, Defective Drugs
A class action was filed in September 2011 against Takeda Pharmaceuticals and Eli Lilly, the manufacturers of the diabetic drug, Actos. The lawsuit was filed in the U.S. District Court for the Eastern District of Louisiana on behalf of two individuals who developed bladder cancer after taking Actos. The complaint also seeks class certification to…
Diabetes Drug, Actos, Linked to Bladder Cancer
By Martin P. Schrama on
Posted in Actos, Defective Drugs
As of August 2011, Actos (Pioglitazone), manufactured by Takeda Pharmaceuticals, was the best selling Type 2 diabetes drug in the world. Introduced to the U.S. market in July 1999, the popularity of the drug has steadily increased over the years, generating over $4 billion in sales in 2010. However, in June 2011, a study of…